These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 17966220)

  • 1. Use of lysophosphatidic acid in the management of benign and malignant ovarian tumors.
    Pozlep B; Meleh M; Kobal B; Verdenik I; Osredkar J; Kralj LZ; Meden-Vrtovec H
    Eur J Gynaecol Oncol; 2007; 28(5):394-9. PubMed ID: 17966220
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers.
    Xu Y; Shen Z; Wiper DW; Wu M; Morton RE; Elson P; Kennedy AW; Belinson J; Markman M; Casey G
    JAMA; 1998 Aug; 280(8):719-23. PubMed ID: 9728644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical significance of plasma lysophosphatidic acid levels in the differential diagnosis of ovarian cancer.
    Zhang YJ; Cao LY; Fu ZZ; Wang YJ; Wang GX; Gu T
    J Cancer Res Ther; 2015; 11(2):375-80. PubMed ID: 26148603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lysophosphatidic acid: an ovarian cancer marker.
    Sedláková I; Vávrová J; Tosner J; Hanousek L
    Eur J Gynaecol Oncol; 2008; 29(5):511-4. PubMed ID: 19051824
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determination of serum lysophosphatidic acid as a potential biomarker for ovarian cancer.
    Meleh M; Pozlep B; Mlakar A; Meden-Vrtovec H; Zupancic-Kralj L
    J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Oct; 858(1-2):287-91. PubMed ID: 17766199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic value of plasma lysophosphatidic acid levels in ovarian cancer patients: A case-control study and updated meta-analysis.
    Cao L; Zhang Y; Fu Z; Dong L; Yang S; Meng W; Li Y; Zhang W; Zhang J; Zheng C; Zhu H; Fan L
    J Obstet Gynaecol Res; 2015 Dec; 41(12):1951-8. PubMed ID: 26472266
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lack of significant differences in the corrected activity of lysophospholipase D, producer of phospholipid mediator lysophosphatidic acid, in incubated serum from women with and without ovarian tumors.
    Tokumura A; Tominaga K; Yasuda K; Kanzaki H; Kogure K; Fukuzawa K
    Cancer; 2002 Jan; 94(1):141-51. PubMed ID: 11815970
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Lysophosphatidic acid in ovarian cancer patients].
    Sedlákova I; Vávrová J; Tosner J; Hanousek L
    Ceska Gynekol; 2006 Jul; 71(4):312-7. PubMed ID: 16956044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lysophosphatidic acid (LPA)—a perspective marker in ovarian cancer.
    Sedláková I; Vávrová J; Tošner J; Hanousek L
    Tumour Biol; 2011 Apr; 32(2):311-6. PubMed ID: 21061112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of CA125/CEA ratio and ultrasound parameters in identifying metastases to the ovaries in patients with multilocular and multilocular-solid ovarian masses.
    Moro F; Pasciuto T; Djokovic D; Di Legge A; Granato V; Moruzzi MC; Mancari R; Zannoni GF; Fischerova D; Franchi D; Scambia G; Testa AC
    Ultrasound Obstet Gynecol; 2019 Jan; 53(1):116-123. PubMed ID: 29978587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validity of colour and pulsed Doppler US and tumour marker CA 125 in differentiation between benign and malignant ovarian masses.
    Antonić J; Rakar S
    Eur J Gynaecol Oncol; 1996; 17(1):29-35. PubMed ID: 8750512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of ultrasound score, CA125, menopausal status, and risk of malignancy index in differentiating between benign and borderline or malignant ovarian tumors.
    Leelahakorn S; Tangjitgamol S; Manusirivithaya S; Thongsuksai P; Jaroenchainon P; Jivangkul C
    J Med Assoc Thai; 2005 Oct; 88 Suppl 2():S22-30. PubMed ID: 17718292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fatty acid composition of lysophosphatidic acid and lysophosphatidylinositol in plasma from patients with ovarian cancer and other gynecological diseases.
    Shen Z; Wu M; Elson P; Kennedy AW; Belinson J; Casey G; Xu Y
    Gynecol Oncol; 2001 Oct; 83(1):25-30. PubMed ID: 11585410
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic value of total plasma lysophosphatidic acid in ovarian cancer: a meta-analysis.
    Lu Z; Chen Y; Hu Z; Hu C
    Int J Gynecol Cancer; 2015 Jan; 25(1):18-23. PubMed ID: 25398018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lysophospholipids are potential biomarkers of ovarian cancer.
    Sutphen R; Xu Y; Wilbanks GD; Fiorica J; Grendys EC; LaPolla JP; Arango H; Hoffman MS; Martino M; Wakeley K; Griffin D; Blanco RW; Cantor AB; Xiao YJ; Krischer JP
    Cancer Epidemiol Biomarkers Prev; 2004 Jul; 13(7):1185-91. PubMed ID: 15247129
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Colour and pulsed Doppler US and tumour marker CA 125 in differentiation between benign and malignant ovarian masses.
    Antonić J; Rakar S
    Anticancer Res; 1995; 15(4):1527-32. PubMed ID: 7654041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of the Ovarian Cancer Biomarker Lysophosphatidic Acid in Serum.
    De La Franier B; Thompson M
    Biosensors (Basel); 2020 Feb; 10(2):. PubMed ID: 32075013
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methods for quantifying lysophosphatidic acid in body fluids: a review.
    Jesionowska A; Cecerska E; Dolegowska B
    Anal Biochem; 2014 May; 453():38-43. PubMed ID: 24613261
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Diagnostic value of CA125, HE4 and Copenhagen Index in differentiating benign from malignant epithelial ovarian tumors].
    Gong SP; Chen YN; Zhang YD; Yao W; Chen L; Liu SS; Wu H
    Nan Fang Yi Ke Da Xue Xue Bao; 2017 May; 37(5):628-632. PubMed ID: 28539285
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of lysophosphatidic acid in vaginal fluid as a biomarker for ovarian cancer: A pilot study.
    Minis E; Holcomb K; Sisti G; Nasioudis D; Kanninen TT; Athanasiou A; Frey MK; Chapman-Davis E; Caputo TA; Witkin SS
    Eur J Obstet Gynecol Reprod Biol X; 2019 Apr; 2():100012. PubMed ID: 31396597
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.